Suven Life Sciences Ltd. has been granted a product patent from Singapore for the New Chemical Entities (NCEs) dealing with treatment of disorders associated with Neurodegenerative diseases. The patent is valid through 2033.

The class of selective 5-HT4 compounds are being developed as therapeutic agents for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.

Suven Life Science is focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class for neurological therapies.

The company has nine internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.